Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib PK and Safety in Advanced Solid Tumors with Renal Impairment
NCT02997163Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of talazoparib in solid tumor (advanced stage) (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration Time Curve From 0 to 24 Hours, Maximum Observed Plasma Concentration at Day 22 and 2 more. Started Feb 2017; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02997163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997163.